Hemopassduo

Hemopassduo is a combination medication that contains acetylsalicylic acid and clopidogrel. It is formulated for oral administration and is marketed in the European Union. The product combines two antiplatelet agents to provide a dual mechanism of action that helps reduce platelet aggregation in patients at risk of thrombotic events.

Hemopassduo is prescribed as part of secondary prevention strategies for cardiovascular conditions where platelet inhibition is required. It is typically used in patients with a history of myocardial infarction, ischemic stroke, or established peripheral arterial disease.

- Reduces risk of recurrent heart attack in patients with prior myocardial infarction. - Helps prevent ischemic stroke in individuals with a history of cerebrovascular events. - Supports management of peripheral arterial disease to lower the chance of limb ischemia. - May be used after coronary artery stenting to maintain vessel patency. - Often prescribed alongside lifestyle modifications and other cardiovascular risk‑reduction measures.

Side‑effect profiles for Hemopassduo reflect the combined actions of aspirin and clopidogrel. Common reactions are usually mild, while serious events are less frequent but require prompt medical attention.

Common: - Gastrointestinal discomfort or dyspepsia. - Minor bruising or easy bleeding of gums. - Headache. - Skin rash or mild itching. - Nausea.

Serious: - Gastrointestinal ulceration or bleeding. - Severe hemorrhage, including intracranial bleeding. - Allergic reactions such as angioedema or anaphylaxis. - Thrombocytopenia (low platelet count). - Hepatic dysfunction indicated by abnormal liver enzymes.

Before initiating Hemopassduo, clinicians should assess patient history and comorbidities to ensure safe use. The following precautions are recommended:

- Verify no active peptic ulcer disease or recent major surgery. - Assess for a history of bleeding disorders or uncontrolled hypertension. - Use caution in patients with asthma or aspirin‑exacerbated respiratory disease. - Evaluate renal and hepatic function periodically during therapy. - Counsel patients on signs of serious bleeding and advise immediate medical attention if they occur. - Avoid use in pregnancy unless clearly indicated, as antiplatelet agents cross the placenta.

Hemopassduo can interact with a range of medications, influencing its antiplatelet efficacy or increasing bleeding risk. Interaction management is essential for patient safety.

Avoid: - Other anticoagulants (e.g., warfarin, direct oral anticoagulants) due to additive bleeding risk. - Non‑steroidal anti‑inflammatory drugs (NSAIDs) that may exacerbate gastrointestinal bleeding. - Selective serotonin reuptake inhibitors (SSRIs) and certain antidepressants that impair platelet function.

Use with caution: - Proton‑pump inhibitors, which may affect clopidogrel activation. - Certain antihypertensives (e.g., ACE inhibitors) that can increase bleeding tendency. - Herbal supplements such as ginkgo biloba, garlic, or high‑dose vitamin E. - Statins metabolized by CYP2C19, which may alter clopidogrel effectiveness.